SCHEMBL14646583

SCHEMBL14646583

CC(C)(C)C[C@@H]1CCCNC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.40
HRH4 Q9H3N8 2/20 0.40
CPN1 P15169 1/20 0.40
CPB2 Q96IY4 1/20 0.40
EED O75530 4/20 0.38
KMT2A Q03164 2/20 0.37
EPHX1 P07099 1/20 0.36
SLC6A1 P30531 2/20 0.34
SLC6A11 P48066 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC6A13 Q9NSD5 1/20 0.34
BACE1 P56817 2/20 0.34
APLNR P35414 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9917291 1.00 HRH3 (0.40) HRH3HRH4CPN1CPB2EED
SCHEMBL14071147 1.00 HRH3 (0.40) HRH3HRH4CPN1CPB2EED
SCHEMBL11915915 0.93 HRH3 (0.35) HRH3HRH4CPN1CPB2EED
SCHEMBL12933065 0.86 SLC6A1 (0.45) HRH3HRH4SLC6A1SLC6A11SLC6A13
SCHEMBL9917290 0.86 SLC6A1 (0.45) HRH3HRH4SLC6A1SLC6A11SLC6A13
SCHEMBL13179816 0.86 SLC6A1 (0.45) HRH3HRH4SLC6A1SLC6A11SLC6A13
SCHEMBL19959236 0.85 CPN1 (0.40) HRH3HRH4CPN1CPB2EED
SCHEMBL20668637 0.84 HRH3 (0.36) HRH3HRH4CPN1CPB2EED
SCHEMBL20668640 0.84 HRH3 (0.36) HRH3HRH4CPN1CPB2EED
SCHEMBL1691733 0.83 HRH3 (0.42) HRH3HRH4CPN1CPB2EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) 2023-07-20 US disclosed
EP-1773869-B9 MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA INC (CA) 2013-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF P2RX3, P2RX4, P2RX7 HRH3 198/4885HRH4 143/4885CPN1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.